The global recombinant plasma protein therapeutics market is expected to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are leading to the growth of the global recombinant plasma protein therapeutics market include the increasing prevalence of autoimmune disorders, immune deficiency disorders, neurological and bleeding disorders. Along with these factors, the rise in the geriatric population across the globe is a major reason for market growth, as elderly people are more prone to neurological disorders. Furthermore, the growing investments in research and development programs by biotechnology and pharmaceutical companies are boosting the market growth.

There has been an increase in the number of regulatory approvals in the last three years that have increased the availability of various options for patients with rare diseases such as haemophilia and other bleeding disorders. These approvals enabled companies to expand their product portfolios and gain a competitive advantage in the global recombinant plasma protein therapeutics market during the forecast period.

The global recombinant plasma protein therapeutics market analysis includes some of the key market players such as Takeda Pharmaceutical Company Ltd, Octapharma USA Inc., Grifols, SA, CSL Behring, Biotest AG, and Baxter, among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. 

Recent Developments:

• In February 2021, Biotest became Germany's first plasma protein manufacturer to produce an investigational hyper immunoglobulin preparation against COVID-19.
• In July 2020, Grifols SA signed an agreement with GC Pharma Group to acquire its Montreal-based plasma fractionation facility and two purification facilities with 11 United States-based plasma collection centers.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Takeda Pharmaceutical Company Ltd, Octapharma USA Inc., Grifols, SA, CSL Behring, Biotest AG, and Baxter, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Recombinant Plasma Protein Therapeutics Market by Segment

By Product

• Immunoglobulin

• Albumin

• Plasma Derived Factor Viii

• Other 

By Application

• Hemophilia

• Idiopathic Thrombocytopenic Purpura

• Primary Immunodeficiencies

• Other

Global Recombinant Plasma Protein Therapeutics Market by Region